LDN Book, Volume Two e-bog
209,76 DKK
(inkl. moms 262,20 DKK)
A comprehensive examination of Low Dose Naltrexone-a little-known drug with big potential"e;[LDN] raises hopes of reversing memory loss in old age."e;-the GuardianA drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike ...
E-bog
209,76 DKK
Forlag
Chelsea Green Publishing
Udgivet
9 oktober 2020
Længde
288 sider
Genrer
Diseases and disorders
Sprog
English
Format
epub
Beskyttelse
LCP
ISBN
9781603589918
A comprehensive examination of Low Dose Naltrexone-a little-known drug with big potential"e;[LDN] raises hopes of reversing memory loss in old age."e;-the GuardianA drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination. LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments.Expanding on the information presented inThe LDN Book, Volume 1,which showcased LDN's efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue,Volume 2highlights the latest clinical trials, case studies, and research with explanations from a dozen medical professionals on how they are using LDN to help patients suffering from:Chronic painParkinson's diseaseDermatologic conditionsTraumatic brain injuryLyme disease and moreThe LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.